371 related articles for article (PubMed ID: 35392233)
1. PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.
Luo Q; Du R; Liu W; Huang G; Dong Z; Li X
Front Oncol; 2022; 12():852383. PubMed ID: 35392233
[TBL] [Abstract][Full Text] [Related]
2. A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma.
Huang R; Dai Q; Yang R; Duan Y; Zhao Q; Haybaeck J; Yang Z
Front Oncol; 2022; 12():817916. PubMed ID: 35574327
[TBL] [Abstract][Full Text] [Related]
3. LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Wang P; Ye H; Wang Y; Ren Y; Zhang J; Lu Z
Onco Targets Ther; 2019; 12():5215-5225. PubMed ID: 31308693
[No Abstract] [Full Text] [Related]
4. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
5. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
6. Silencing UHRF1 Enhances Radiosensitivity of Esophageal Squamous Cell Carcinoma by Inhibiting the PI3K/Akt/mTOR Signaling Pathway.
Hui B; Pan S; Che S; Sun Y; Yan Y; Guo J; Gong T; Ren J; Zhang X
Cancer Manag Res; 2021; 13():4841-4852. PubMed ID: 34188537
[TBL] [Abstract][Full Text] [Related]
7. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
[TBL] [Abstract][Full Text] [Related]
8. Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis
Guo J; Zhang S; Wang J; Zhang P; Lu T; Zhang L
Front Oncol; 2022; 12():833719. PubMed ID: 35178352
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma
Hu DX; Sun QF; Xu L; Lu HD; Zhang F; Li ZM; Zhang MY
World J Gastroenterol; 2022 Jan; 28(4):464-478. PubMed ID: 35125830
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
11. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
Lu Z; Shi X; Gong F; Li S; Wang Y; Ren Y; Zhang M; Yu B; Li Y; Zhao W; Zhang J; Hou G
Acta Pharm Sin B; 2020 Jun; 10(6):1004-1019. PubMed ID: 32642408
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway.
Zhang Y; Chen W; Wang H; Pan T; Zhang Y; Li C
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1209-1218. PubMed ID: 31529206
[TBL] [Abstract][Full Text] [Related]
13. Homeobox D10, a tumor suppressor, inhibits the proliferation and migration of esophageal squamous cell carcinoma.
Zhang J; Liu S; Zhang D; Ma Z; Sun L
J Cell Biochem; 2019 Aug; 120(8):13717-13725. PubMed ID: 30938888
[TBL] [Abstract][Full Text] [Related]
14. HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo.
Xi R; Pan S; Chen X; Hui B; Zhang L; Fu S; Li X; Zhang X; Gong T; Guo J; Zhang X; Che S
Oncotarget; 2016 Aug; 7(35):57050-57065. PubMed ID: 27489353
[TBL] [Abstract][Full Text] [Related]
15. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
17. MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway.
Guanen Q; Junjie S; Baolin W; Chaoyang W; Yajuan Y; Jing L; Junpeng L; Gaili N; Zhongping W; Jun W
Biomed Pharmacother; 2018 Sep; 105():350-361. PubMed ID: 29864623
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway.
Ma S; Liu T; Xu L; Wang Y; Zhou J; Huang T; Li P; Liu H; Zhang Y; Zhou X; Cui Y; Zang X; Wang Y; Guan F
J Cell Physiol; 2019 Dec; 234(12):22400-22410. PubMed ID: 31120582
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
Wang SQ; Wang X; Zheng K; Liu KS; Wang SX; Xie CH
Biochem Biophys Res Commun; 2017 Nov; 493(1):534-541. PubMed ID: 28867195
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
